Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

See How to

Filter conferences

12th Tumor Models Boston

12th Tumor Models Boston


Date of beginning

Tuesday, 23 July 2024


2 days




United States


Alex Domingo


This email address is being protected from spambots. You need JavaScript enabled to view it.


In the wake of the FDA Modernization Act and translational rates of cancer drugs into the clinic at just 20%, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery. The 12th Annual Tumor Models Boston Summit is the only industry-led meeting uniting 200+ industry experts from pharma, biotech, academic KOLs and preclinical CROs to delve into the latest case studies in leveraging PDX models, genetically engineered mouse models, advanced 3D in vitro models and more. Join industry leaders developing teams in preclinical, translational, pharmacology, discovery, pharmacodynamics, toxicity and biology to optimize and implement more translatable oncology models. URLs:Tickets: Brochure: Date and Time: On Tue, 23 Jul 2024 08:00 - Wed, 24 Jul 2024 16:10 Venue Details: The Westin Boston Seaport District, 425 Summer Street, Boston, Massachusetts, 02210, United States Prices:Drug Developer, Researchers and Academic - 2 Day Conference Pass: USD 0.50,Solution Provider - 2 Day Conference Pass: USD 3699.00 Speakers: Alexander Adler, Principal Scientist and Research Associate, Regeneron Pharmaceuticals Inc, Alina Ainbinder, Principal Scientist, Takeda Pharmaceuticals Co. Ltd., Bin Xie, Director of Immuno-Oncology, Shanghai LIDE Biotech., Co.Ltd., Colles Price, Principal Scientist, Takeda Pharmaceuticals Co. Ltd., Deepali, Sawant, Senior Principal Scientist, Amgen Inc., Emily Mason-Osann, Senior Scientist, AstraZeneca, Francesca Barone M.D., Ph.D., Chief Scientific Officer, Candel Therapeutics, Hongyu Xue, Director In Vivo Pharmacology, Oncology Research, Bayer, Jing Jiao, Senior Principal Scientist, Sanofi, Justine Roderick-Richardson, Scientist, AstraZeneca, Katja Mohrs, Principal Scientist, Regeneron Pharmaceuticals Inc, Ludovic Bigot, Project Manager, Institut Gustave Roussy, Mark Wood, Former Senior Scientist - Research and Pharmacology, Vertex Pharmaceuticals, Michael Buckenmeyer, Postdoctoral Fellow, National Cancer Institute, Pengyu Huang, Principal Scientist and Head of In Vivo Pharmacology, Simcere Innovation Inc., Poonam Yakkundi, Senior Scientist, IGM Biosciences, Regina Reilly, Research Fellow, Abbvie, Reshma Singh, Head of Oncology Early Translation, Takeda Pharmaceuticals Co. Ltd., Robert Mihalek, Principal Scientist and Associate Director - Pharmacology and Oncology, Charles River Laboratories, Sreedhar Reddy Suthe, Principal Scientist, BrickBio, Tamar Uziel, Scientific Director, Research Fellow; Precision Medicine Oncology, Translational Research, Lead, Abbvie, Tapan Nayak, Senior Director - Translational Imaging and Translational Medicine, Merck and Co, Zohreh Amoozgar, Pricipal Scientist and Lab Head, Sanofi